| 000 | 01961naaaa2200301uu 4500 | ||
|---|---|---|---|
| 001 | https://directory.doabooks.org/handle/20.500.12854/66566 | ||
| 005 | 20220220083257.0 | ||
| 020 | _a45910 | ||
| 020 | _a9789535111641 | ||
| 020 | _a9789535171652 | ||
| 024 | 7 |
_a10.5772/45910 _cdoi |
|
| 041 | 0 | _aEnglish | |
| 042 | _adc | ||
| 072 | 7 |
_aMJQ _2bicssc |
|
| 100 | 1 |
_aAguilera Peralta, Abelardo _4edt |
|
| 700 | 1 |
_aAguilera Peralta, Abelardo _4oth |
|
| 245 | 1 | 0 | _aThe Latest in Peritoneal Dialysis |
| 260 |
_bIntechOpen _c2013 |
||
| 300 | _a1 electronic resource (116 p.) | ||
| 506 | 0 |
_aOpen Access _2star _fUnrestricted online access |
|
| 520 | _aThis book summarizes the advances and new concepts introduced in the last years on peritoneal dialysis (PD) and its complications. PD therapy is a renal replacement peritoneal membrane using a semi-permeable barrier to liquids and solutes. The abdominal cavity with all its components, mesothelial cells, fat tissue, immune system components and others are activated by the PD fluids that although every time are more biocompatible, induce production of molecules with the local and systemic effects. Locally there is a thickening of the peritoneal membrane leading to the failure of this and where the transdifferentiation of mesothelial cells plays a key role. Systemically activating abdominal cavity appears to be involved in atherosclerosis, diabetes, hypertension, renal bone disease pathway and others. | ||
| 540 |
_aCreative Commons _fhttps://creativecommons.org/licenses/by/3.0/ _2cc _4https://creativecommons.org/licenses/by/3.0/ |
||
| 546 | _aEnglish | ||
| 650 | 7 |
_aOphthalmology _2bicssc |
|
| 653 | _aRenal medicine & nephrology | ||
| 856 | 4 | 0 |
_awww.oapen.org _uhttps://mts.intechopen.com/storage/books/3258/authors_book/authors_book.pdf _70 _zDOAB: download the publication |
| 856 | 4 | 0 |
_awww.oapen.org _uhttps://directory.doabooks.org/handle/20.500.12854/66566 _70 _zDOAB: description of the publication |
| 999 |
_c76177 _d76177 |
||